Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927719 · ClinicalTrials.gov registry record
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
A clinical trial of Smallpox, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- 897,227
- Enrollment target
- 4
- Study locations
NCT00927719 is a study of Smallpox that has completed, run by Emergent BioSolutions. The registered enrollment target is 897,227 participants, above the 2,876-participant average among 7 other Smallpox trials with a reported enrollment target (31097% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT00927719, a study of Smallpox, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- 897,227 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: * To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in temporal association with ACAM2000® vaccination. Secondary Objectives: * To evaluate the rates of cardiovascular adverse events in temporal association with ACAM2000® vaccination. * To evaluate the rates of neurological adverse events in temporal association with ACAM2000® vaccination.
Conditions Studied
Interventions
- BIOLOGICAL ACAM2000® smallpox vaccine
Study Locations (4)
Texas
- - Fort Bliss
- - Fort Hood
California
- - Twentynine Palms
Kentucky
- - Fort Campbell North
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 897,227 participants |
| Start Date | 2008-12 |
| Est. Completion | 2017-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927719
The ClinicalTrials.gov registry entry for NCT00927719 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 897,227 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,876-participant average among 7 other Smallpox trials with a reported enrollment target (31097% higher). The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 1 intervention - of which ACAM2000® smallpox vaccine is the first listed.
NCT00927719 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00927719 about?
NCT00927719 is a clinical study titled "Safety Surveillance Study of ACAM2000® Vaccinia Vaccine". This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: * To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in temporal association with ACAM2000® vaccination. Secondary Objectives: ...
What is the current status of trial NCT00927719?
This trial is currently completed. The enrollment target is 897,227 participants. The study started on 2008-12. Estimated completion is 2017-12-31.
What conditions does trial NCT00927719 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT00927719?
The interventions under investigation include: ACAM2000® smallpox vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00927719?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927719 being conducted?
This trial has 4 study locations across California, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
MVA Post-Event: Administration Timing and Boost Study
COMPLETED · Phase 1
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.